CASTLE ROCK, Colo.
May 30, 2013
(Nasdaq: APPY), an
diagnostic company focused on obtaining FDA clearance and commercializing its rapid, protein biomarker-based appendicitis test,
, today announced the closing of its previously announced underwritten public offering. The underwriter fully exercised its option to purchase additional shares of common stock and related warrants to cover over-allotments, resulting in the sale of 11,500,000 shares of common stock and related warrants to purchase up to 4,025,000 shares of common stock, at an exercise price of
per share, at a combined public offering price of
per share and related warrant. The gross proceeds to Venaxis from this offering were approximately
, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Venaxis and excluding the proceeds, if any, from the exercise of warrants.
Piper Jaffray & Co. acted as sole manager for the offering.
Venaxis anticipates using the net proceeds from the offering for working capital and other general corporate purposes, including funding for further clinical development, seeking FDA clearance for
, and for initial commercialization of
in the U.S. and the E.U.
"The closing of this offering is a significant milestone for Venaxis," stated
, President and CEO. "We now have the funds to complete the FDA's clearance process and implement initial commercial milestones necessary to bring the
test into the hands of hospitals and clinicians in
the United States
. We look forward to continuing to execute our commercial plan, which currently includes focused market development activities in
is CE Marked, as well as in the U.S., where we anticipate completing the pivotal clinical trial in late 2013 and thereafter filing for FDA clearance."
This offering was made pursuant to a final prospectus relating to the offering that was filed with the Securities and Exchange Commission on
May 24, 2013
. Copies of the final prospectus relating to the offering may be obtained from the Securities and Exchange Commission website at
, or from the underwriters at Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
55402, via telephone at 800-747-3924 or email at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.